Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL

Journal of Lipid Research

Volumn 50, Issue 4, 2009, Pages 641-650

  Boyanovsky, Boris B ^a   Shridas, Preetha ^a   Simons, Michael ^b   van der Westhuyzen, Deneys R ^a   Webb, Nancy R ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Foam cells; Lipoprotein modification; Macropinocytosis; Proteoglycan

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHOLESTEROL ESTER; IODINE 125; LIPOPOLYSACCHARIDE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; SECRETORY PHOSPHOLIPASE A2; SMALL INTERFERING RNA; SYNDECAN 4; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; PHOSPHOLIPASE A2 GROUP V; PRIMER DNA; SDC3 PROTEIN, MOUSE; SDC4 PROTEIN, MOUSE; SYNDECAN 3;

ANIMAL CELL; ARTICLE; BINDING SITE; C57BL 6 MOUSE; CELL LABELING; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE SILENCING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CELL CULTURE; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE;

ANIMALS; ATHEROSCLEROSIS; BASE SEQUENCE; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELLS, CULTURED; CHROMONES; DNA PRIMERS; GENE EXPRESSION; GROUP V PHOSPHOLIPASES A2; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; PINOCYTOSIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SYNDECAN-3; SYNDECAN-4;

EID: 67449168509     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800450-JLR200     Document Type: Article

References (44)

1. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15: 551-561.
2. Tabas, I., K. J. Williams, and J. Boren. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116: 1832-1844.
3. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
4. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478.
5. Xu, X. X., and I. Tabas. 1991. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J. Biol. Chem. 266: 24849-24858.
6. Hakala, J. K., K. Oorni, M. O. Pentikainen, E. Hurt-Camejo, and P. T. Kovanen. 2001. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21: 1053-1058.
7. Oorni, K., P. Posio, M. Ala-Korpela, M. Jauhiainen, and P. T. Kovanen. 2005. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler. Thromb. Vasc. Biol. 25: 1678-1683.
8. Gesquiere, L., W. Cho, and P. V. Subbaiah. 2002. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry. 41: 4911-4920.
9. Pruzanski, W., L. Lambeau, M. Lazdunsky, W. Cho, J. Kopilov, and A. Kuksis. 2005. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim. Biophys. Acta. 1736: 38-50.
10. Sato, H., R. Kato, Y. Isogai, G-i. Saka, M. Ohtsuki, Y. Taketomi, K. Yamamoto, K. Tsutsumi, J. Yamada, S. Masuda, et al. 2008. Analyses of group III secreted phospholipase A2 transgenic mice reveals potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J. Biol. Chem. 283: 33483-33497.
11. Bostrom, M. A., B. B. Boyanovsky, C. T. Jordan, M. P. Wadsworth, D. J. Taatjes, F. C. de Beer, and N. R. Webb. 2007. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler. Thromb. Vasc. Biol. 27: 600-606.
12. Rosengren, B., H. Peilot, M. Umaerus, A-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo. 2006. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler. Thromb. Vasc. Biol. 26: 1579-1585.
13. Flood, C., M. Gustafsson, R. E. Pitas, L. Arnaboldi, R. L. Walzem, and J. Boren. 2004. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler. Thromb. Vasc. Biol. 24: 564-570.
14. Wooton-Kee, C. R., B. B. Boyanovsky, M. S. Nasser, W. J. de Villiers, and N. R. Webb. 2004. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 24: 762-767.
15. Boyanovsky, B. B., D. R. van der Westhuyzen, and N. R. Webb. 2005. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J. Biol. Chem. 280: 32746-32752.
16. Febbraio, M., N. A. Abumrad, D. P. Hajjar, K. Sharma, W. Cheng, S. F. A. Pearce, and R. L. Silverstein. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274: 19055-19062.
17. Ishiguro, K., K. Kadomatsu, T. Kojima, H. Muramatsu, S. Tsuzuki, E. Nakamura, K. Kusugami, H. Saito, and T. Muramatsu. 2000. Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions. J. Biol. Chem. 275: 5249-5252.
18. Sartipy, P., B. Johansen, G. Camejo, B. Rosengren, G. Bondjers, and E. Hurt-Camejo. 1996. Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J. Biol. Chem. 271: 26307-26314.
19. Noble, R. P. 1968. Electrophoretic separation of plasma lipoproteins in agarose gel. J. Lipid Res. 9: 693-700.
20. Kunjathoor, V. V., M. Febbraio, E. A. Podrez, K. J. Moore, L. Andersson, S. Koehn, J. S. Rhee, R. Silverstein, H. F. Hoff, and M. W. Freeman. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277: 49982-49988.
21. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
22. Tkachenko, E., E. Lutgens, R-V. Stan, and M. Simons. 2004. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J. Cell. Sci. 117: 3189-3199.
23. Carr, T. P., C. J. Andresen, and L. L. Rudel. 1993. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26: 39-42.
24. Williams, K. J., G. M. Fless, K. A. Petrie, M. L. Snyder, R. W. Brocia, and T. L. Swenson. 1992. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. 267: 13284-13292.
25. Hoogewerf, A. J., L. A. Cisar, D. C. Evans, and A. Bensadoun. 1991. Effect of chlorate on the sulfation of lipoprotein lipase and heparan sulfate proteoglycans. Sulfation of heparan sulfate proteoglycans affects lipoprotein lipase degradation. J. Biol. Chem. 266: 16564-16571.
26. Kruth, H. S., N. L. Jones, W. Huang, B. Zhao, I. Ishii, J. Chang, C. A. Combs, D. Malide, and W-Y. Zhang. 2005. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280: 2352-2360.
27. Fuki, I. V., K. M. Kuhn, I. R. Lomazov, V. L. Rothman, G. P. Tuszynski, R. V. Iozzo, T. L. Swenson, E. A. Fisher, and K. J. Williams. 1997. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100: 1611-1622.
28. Bernfield, M., R. Kokenyesi, M. Kato, M. T. Hinkes, J. Spring, R. L. Gallo, and E. J. Lose. 1992. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8: 365-393.
29. Carey, D. J., D. M. Evans, R. C. Stahl, V. K. Asundi, K. J. Conner, P. Garbes, and G. Cizmeci-Smith. 1992. Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan. J. Cell Biol. 117: 191-201.
30. Ishiguro, K., K. Kadomatsu, T. Kojima, H. Muramatsu, M. Iwase, Y. Yoshikai, M. Yanada, K. Yamamoto, T. Matsushita, M. Nishimura, et al. 2001. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J. Biol. Chem. 276: 47483-47488.
31. Murakami, M., and I. Kudo. 2003. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr. Opin. Lipidol. 14: 431-436.
32. Webb, N. R. 2005. Secretory phospholipase A2 enzymes in atherogenesis. Curr. Opin. Lipidol. 16: 341-344.
33. Fuki, I. V., M. E. Meyer, and K. J. Williams. 2000. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem. J. 351: 607-612.
34. Tkachenko, E., J. M. Rhodes, and M. Simons. 2005. Syndecans: new kids on the signaling block. Circ. Res. 96: 488-500.
35. Hayashi, K., J. A. Madri, and P. D. Yurchenco. 1992. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J. Cell Biol. 119: 945-959.
36. Fuki, I. V., R. V. Iozzo, and K. J. Williams. 2000. Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J. Biol. Chem. 275: 25742-25750.
37. Hanasaki, K., K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, T. Ono, M. Ikeda, M. Notoya, S. Kamitani, and H. Arita. 2002. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277: 29116-29124.
38. Wilsie, L. C., A. M. Gonzales, and R. A. Orlando. 2006. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway. Lipids Health Dis. 5: 23-36.
39. Araki, N., M. T. Johnson, and J. A. Swanson. 1996. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J. Cell Biol. 135: 1249-1260.
40. Kjellen, L., D. Bielefeld, and M. Hook. 1983. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes. 32: 337-342.
41. Ebara, T., K. Conde, Y. Kako, Y. Liu, Y. Xu, R. Ramakrishnan, I. J. Goldberg, and N. S. Shachter. 2000. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J. Clin. Invest. 105: 1807-1818.
42. Houston, M., M. A. Julien, S. Parthasarathy, and E. L. Chaikof. 2005. Oxidized linoleic acid regulates expression and shedding of syndecan-4. Am. J. Physiol. Cell Physiol. 288: C458-C466.
43. Smith, S., S. Mountcastle, A. Burridge, T. F. Dodson, A. A. Salam, K. Kasirajan, R. Milner, R. Veeraswamy, and E. L. Chaikof. 2008. A single-institution experience with the aneurx stent graft for endovascular repair of abdominal aortic aneurysm. Ann. Vasc. Surg. 22: 221-226.
44. Li, L., T. L. Couse, H. DeLeon, C. P. Xu, J. N. Wilcox, and E. L. Chaikof. 2002. Regulation of syndecan-4 expression with mechanical stress during the development of angioplasty-induced intimal thickening. J. Vasc. Surg. 36: 361-370.